Using a new treatment to reduce inflammation and oxidative stress in acute lung injury
Targeting inflammation and oxidative stress to treat acute lung injury with CNP-miR146a
This study is testing a new treatment called CTX-002, which uses tiny particles to help reduce inflammation and stress in the lungs for people with acute lung injury and ARDS, with the hope of improving their recovery and overall health.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ceria Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Tucson, UNITED STATES) |
| Project ID | NIH-10930131 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapy, CTX-002, to treat acute lung injury and acute respiratory distress syndrome (ARDS) by targeting inflammation and oxidative stress. The approach involves using cerium oxide nanoparticles that can scavenge reactive oxygen species and reduce inflammation in the lungs. Patients with ARDS often face severe complications, and this treatment aims to improve their outcomes by addressing the underlying causes of lung injury. The research will involve clinical trials to assess the safety and effectiveness of this new therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute lung injury or ARDS, particularly those experiencing severe respiratory distress.
Not a fit: Patients with chronic lung diseases or those who do not have acute lung injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly improves recovery and survival rates for patients with acute lung injury and ARDS.
How similar studies have performed: While targeting inflammation and oxidative stress in lung injury is a promising approach, this specific treatment using cerium oxide nanoparticles is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Tucson, UNITED STATES
- Ceria Therapeutics, INC. — Tucson, United States (Active)
Researchers
- Principal investigator: Jackson, David — Ceria Therapeutics, INC.
- Study coordinator: Jackson, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.